Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease

Expert Review of Clinical Immunology

Volumn 6, Issue 4, 2010, Pages 607-620

  Shah, Brijen ^a   Mayer, Lloyd ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Crohns disease; infusion reaction; monoclonal antibody; tumor necrosis factor; ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBODY; ANTIHISTAMINIC AGENT; BASILIXIMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DACLIZUMAB; DIPHENHYDRAMINE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NATALIZUMAB; PARACETAMOL; PLACEBO; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB;

ANUS FISTULA; AUTOIMMUNITY; CLINICAL TRIAL; CROHN DISEASE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; ENTERITIS; HUMAN; IMMUNOREACTIVITY; INFUSION RATE; INFUSION REACT; INFUSION REACTION; LYMPHOMA; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; REMISSION; REVIEW; SEPSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77954420619     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.45     Document Type: Review

References (101)

1. Loftus EV, Sandborn WJ. Epidemiology of infammatory bowel disease. Gastroenterol. Clin. North. Am. 31(1), 1-20 (2002).
2. Abraham C, Cho J. Infammatory bowel disease. N. Engl. J. Med. 361(21), 2066-2078 (2009).
3. Van Deventer SJ. Tumor necrosis factor and Crohn's disease. Gut 40(4), 443-448 (1997). (Pubitemid 27204920)
4. Rescigno M, Urbano M, Wazasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2(4), 361-367 (2001). (Pubitemid 33706348)
5. Niess JH, Brand S, Gu X et al. CX3-CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307(5707), 254-258 (2005). (Pubitemid 40116240)
6. Lorenz RG, Newberry RD. Isolated lymphoid follicles can function as sites for induction of mucosal immune responses. Ann. NY Acad. Sci. 1029, 44-57 (2004).
7. Johansson C, Kelsall BL. Phenotype and function of intestinal dendritic cells. Semin. Immunol. 17(4), 284-294 (2005). (Pubitemid 40981933)
8. Danese S, Semerraro S, Marini M et al. Adhesion molecules in infammatory bowel disease: therapeutic implications for gut infammation. Dig. Liver Dis. 37(11), 811-818 (2005). (Pubitemid 44356115)
9. Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of infammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J. Gastroenterol. 12(29), 4628-4635 (2006). (Pubitemid 44269718)
10. Hynes RO. Integrins: bidirection, allosteric signalling machines. Cell 110(6), 673-687 (2002).
11. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-a monoclonal antibody bind recombinant transmembrane TNF-a and activates immune effector functions. Cytokine 7(3), 15-25(1995).
12. Targan S, Hanauer S, van Deventer S et al A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N. Engl. J. Med. 337(15), 1029-1035 (1997). (Pubitemid 27430520)
13. Miheller P, Lakatos PL, Horvath G et al. Effcacy and safety of infiximab induction therapy in Crohn's disease in central Europe-a Hungarian nationwide observational study. BMC Gastro. 9, 66 (2009).
14. Ardizzone S, Colombo E, Maconi G et al. Infiximab in treatment of Crohn's disease: the Milan experience. Dig. Liver Dis. 34(6), 411-418 (2002). (Pubitemid 34679063)
15. Hanauer S, Faegan B, Lichtenstein G et al. Maintenance infiximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359(9317), 1541-1549 (2002). (Pubitemid 34621118)
16. Rutgeerts P, Feagan B, Lichtenstein G et al. Comparison of scheduled and episodic treatment strategies of infiximab in Crohn's disease. Gastroenterology 126(2), 402-413 (2004). (Pubitemid 38182297)
17. Schnitzler F, Fidder H, Ferrante M et al. Long term outcome of treatment with infiximab in 614 patients with Crohn's disease: results from a single-center cohort. Gut 58(4), 492-500 (2009).
18. Williams DR, Collier JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis. Colon Rectum 24(1), 22-24 (1981).
19. Present, D, Rutgeerts P, Targan S et al. Infiximab for the treatment of fstulas in patients with Crohn's disease. N. Engl. J. Med. 340(18), 1398-1405 (1999). (Pubitemid 29205403)
20. Ng SC, Plamondon S, Gupta A et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fstulas. Am. J. Gastroenterol. 104(12), 2973-2986 (2009).
21. Schwartz D. Imaging and the treatment of Crohn's perianal fstulas: to see is to believe. Am. J. Gastroenterol. 104(12), 2987-2989 (2009).
22. Tougeron D, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fstula healing and clinical remission after infiximab-based combined therapy for perianal fstulizing Crohn's disease. Dig. Dis. Sci. 54(8), 1746-1752 (2009).
23. Bouguen L, Trouilloud I, Siproudhis L et al. Long-term outcome of non-fstulizing (ulcer, stricture) perianal Crohn's disease in patients treated with infiximab. Aliment Pharmacol. Ther. 30(7), 749-756 (2009).
24. Sands BE, Anderson FH, Bernstein CN et al. Infiximab maintenance therapy for fstulizing Crohn's disease. N. Engl. J. Med. 350(9), 876-885 (2004). (Pubitemid 38252535)
25. Regueiro M, Schraut W, Baidoo L et al. Infiximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136(2), 441-450 (2009).
26. Hanauer S, Sandborn W, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130(2), 323-333 (2006). (Pubitemid 43202032)
27. Sandborn W, Hanauer S, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56(9), 1232-1239 (2007). (Pubitemid 47300424)
28. Lofberg R, Louis E, Reinisch W et al. Adalimumab effectiveness in TNF-antagonist-naïve patients and in infiximab nonresponders with Crohn' disease: results from the CARE study. Am. J. Gastroenterol. 103(S1), S418 (2008).
29. Colombel, JF, Sandborn W, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1), 52-65 (2007). (Pubitemid 46108762)
30. Colombel JF, Sandborn W, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am. J. Gastroenterol. 104(5), 1170-1179 (2009).
31. Feagan B, Panaccione R, Sandborn W et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135(5), 1493-1499 (2008).
32. Sandborn W, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infiximab. Ann. Intern. Med. 146(12), 829-838 (2007).
33. Mannon P, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351(20), 2069-2079 (2004). (Pubitemid 39482500)
34. Nebitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti tumor necrosis factor a agents. Infamm. Bowel Dis. 13(11), 1323-1332 (2007). (Pubitemid 350206841)
35. Fossati G, Nebitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infiximab, and certolizumab pegol. Am. J. Gastroenterol. 100, S299 (2005).
36. Sandborn W, Feagan B, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007). (Pubitemid 47080387)
37. Schoepfer AM, Vavricka SR, Binek J et al. Effcacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Infamm. Bowel Dis. 16(6), 933-938 (2010).
38. Schriber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol for treatment of Crohn's disease. Gastroenterology 129(3), 807-818 (2005). (Pubitemid 41242673)
39. Schreiber S, Khaliq-Kareemi K, Lawrance I et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357(3), 239-250 (2007). (Pubitemid 47080388)
40. Lichtenstein GR, Thomsen OO, Schriber S et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin. Gastroenterol. Hepatol. DOI:10.1016/j.cgh.2010.01.014 (2010) (Epub ahead of print).
41. Danese S, Mocciaro F, Guidi L et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infiximab: a real-life multicenter experience of compassionate use. Infamm. Bowel Dis. 14(8), 1168-1170 (2008).
42. Ringheanu M, Daum F, Markowitz J et al. Effects of infiximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Infamm. Bowel Dis. 10(6), 801-810 (2004). (Pubitemid 39545226)
43. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infiximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest. Endosc. 63(3), 433-442 (2006). (Pubitemid 43261469)
44. Colombel J, Sandborn W, Reinisch W et al. Infiximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362(15), 1383-1395 (2010).
45. Binion DG, West GA, Volk EE et al. Acquired increase in leukocyte binding by intestinal microvascular endothelium in infammatory bowel disease. Lancet 352(9142), 1742-1746 (1998).
46. Gordon FH, Clement WYL, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to a4 interferon in active Crohn's disease. Gastroenterology 121(2), 268-274 (2001). (Pubitemid 32729374)
47. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348(1), 24-32 (2003). (Pubitemid 36026343)
48. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005). (Pubitemid 41565956)
49. Targan SR, Feagan BG, Fedoral RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132(5), 1672-1683 (2007). (Pubitemid 46695722)
50. Chen Y, Bord E, Thompkins T et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361(11), 1067-1074 (2009).
51. Sandborn W, Hanauer S, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001). (Pubitemid 33022088)
52. Braegger CP, Nicholls S, Murch SH et al. Tumor necrosis factor a in stool as a marker of intestinal infammation. Lancet 338(8785), 89-91 (1992).
53. Nielsen OH, Gionchetti P, Ainsworth M et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin interleukin-8, and tumor necrosis factor-a in ulcerative colitis. Am. J. Gastroenterol. 94(10), 2923-2928 (1999). (Pubitemid 29482759)
54. Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumor necrosis factor a in childhood chronic infammatory bowel disease. Gut 32(8), 913-917 (1991).
55. Watkins PE, Warren BF, Stephen S, Ward P, Foulkes R. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor a. Gut 40(5), 628-633 (1997). (Pubitemid 27278331)
56. Sands, B, Tremain W, Sandborn W et al. Infiximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Infamm. Bowel Dis. 7(2), 83-88 (2001). (Pubitemid 32998493)
57. Probert CS, Hearing SD, Schreiber S et al. Infiximab in a moderately sever glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut 52(7), 998-1002 (2003). (Pubitemid 36765292)
58. Kohn A, Prantera C, Pera A et al. Anti-tumor necrosis factor in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig. Liver Dis. 34(9), 626-630 (2002).
59. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infiximab for treatment of steroid-refractory ulcerative colitis. Dig. Liver Dis. 34(9), 631-634 (2002).
60. Su C, Salzberg BA, Lewis JD et al. Effcacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 97(10), 2577-2584 (2002).
61. Rutgeerts P, Sandborn W, Feagan B et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)
62. Jarnerot G, Hertervig E, Friis-Liby I et al. Infiximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (7), 1805-1811 (2005). (Pubitemid 40824691)
63. Bressler B, Law JK, Sheraisher N et al. The use of infiximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can. J. Gastroenterol. 22(11), 937-940 (2008).
64. Sandborn W, Rutgeerts P, Feagan B et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infiximab. Gastroenterology 137(4), 1250-1260 (2009).
65. Russo EA, Harris AW, Campbell S et al. Experience of maintenance infiximab therapy for refractory ulcerative colitis from six centers in England. Aliment. Pharmacol. Ther. 29(3), 308-314 (2009).
66. Maser EA, Deconda D, Lichtiger S et al. Cyclosporine and infiximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6(10), 1112-1116 (2008).
67. Leblanc S, Allez M, Seksik P et al. Successive treatment with cyclosporine and infiximab of severe ulcerative colitis. Gut 57(S2), A66 (2008).
68. Manosa M, San roman A, Garcia-Planella E et al. Infiximab rescue therapy after cyclosporine failure in steroid-refractory ulcerative colitis. Digestion 80(1), 30-35 (2009).
69. Ulich TE, del Castillo J, Keys M et al. Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-a-induced changes in circulating numbers of neutrophils and lymphocytes. Immunology 139(10), 3406-3415 (1987). (Pubitemid 18021995)
70. Sugarman B, Aggarwal B, Hass P, Figari IS, Palladino MA Jr, Shepard HM. Recombinant human tumor necrosis factor-a effects on profieration of normal and transformed cell in vitro. Science 230(4728), 943-945 (1985). (Pubitemid 16193990)
71. Postlethwaite AE, Seyer JM. Stimulation of fbroblast chemotaxis by human recombinant tumor necrosis factor and a synthetic TNF-a 31-68 peptide. J. Exp. Med. 172(6), 1749-1756 (1990).
72. Schluender S, Ippoliti A, Dubinsky M et al. Does infiximab infuence surgical morbidity of ileal pouch-anal anastamosis in patients with ulcerative colitis? Dis. Colon Rectum 50(11), 1747-1753 (2007). (Pubitemid 350077092)
73. Yang Z, Wu Q, Wu K et al. Meta-analysis: pre-operative infiximab treatment and short-term postoperative complication in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 31(4), 486-492 (2010).
74. Penna C, Dozois R, Tremaine W et al. Pouchitis after ileal pouch-anal anastamosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 38(2), 234-239 (1996). (Pubitemid 26046819)
75. Viscido A, Habib F, Kohn A et al. Infiximab for refractory pouchitis complicated by fstula following ileo-anal pouch for ulcerative colitis. Aliment.Pharmacol. Ther. 17(10), 1263-1271 (2003). (Pubitemid 36693727)
76. Aff W, Leighton J., Hanauer S et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infiximab. Infamm. Bowel Dis. 15(9), 1302-1307 (2009).
77. Barreiro-de-Acosta M., Lorenzo A, Dominguez-Munoz J. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J. Gastroenterol. 15(30), 3814-3816 (2009).
78. Oussalah A, Laclotte C, Chevaux JB et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infiximab: a single-centre experience. Aliment. Pharmacol. Ther. 28(8), 966-972 (2008).
79. Caviglia R, Boskoski, Cicala C et al. Long-term treatment with infiximab infammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7(5), 617-632 (2008).
80. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52(6), 1766-1772 (2005). (Pubitemid 40852885)
81. Millonig G, kern M, Ludwiczek O et al. Subfulminant hepatitis B after infiximab in Crohn's disease: need for HBV-screening? World J. Gastroenterol. 12(6), 974-976 (2006).
82. Peyrin-Biroulet, L, Pierre D, De Suray N, Branche J, Sandborn WJ, Colombel JF. Effcacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008). (Pubitemid 351783447)
83. Colombel JF, Sandborn WJ, Rutgeerts P et al. The safety profle of infiximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1), 19-31 (2004).
84. Tsiodras S, Samonis G, Boumpas DT et al. Fungal infection complication tumor necrosis factor a blockade therapy. Mayo Clin. Proc. 83(2), 181-194 (2008). (Pubitemid 351303102)
85. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 4(5), 621-630 (2006).
86. Jones JL, Loftus EV. Lymphoma risk in infammatory bowel disease: is it the disease or its treatment? Infamm. Bowel Dis. 13(10), 1299-1307 (2007). (Pubitemid 47597781)
87. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in infammatory bowel disease. Gut 57(12), 1639-1641 (2008).
88. Ochenrider MG, Patterson DJ, Aboulafa DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: a case report and literature review. Clin. Lymphoma Myeloma 10(2), 144-148 (2010).
89. Aarden L, Ruuls S, Wolbink G. Immunogencity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20(4), 431-435 (2008).
90. Hanauer S, Wagner C, Bala M et al. Incidence and important of antibody responses to infiximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2(7), 542-553 (2004). (Pubitemid 38834038)
91. Baert F, Noman M, Vermerire S et al. Infuence of immunogenicity on the long-term effcacy of infiximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003). (Pubitemid 36204954)
92. Mayer L, Young Y Infusion reactions and their management. Gastroenterol. Clin. North. Am. 35(4), 857-866 (2006). (Pubitemid 44791840)
93. Vermeire S, Noman M, Can Assche G et al. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125(1), 32-39 (2003). (Pubitemid 36799104)
94. Bell TM, Bansal AS, Shorthous C et al. Low-titer autoantibodies predict autoimmune disease during interferon-a treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 14(5), 419-422 (1999).
95. Schaible TF. Long term safety of infiximab. Can. J. Gastroenterol. 14(Suppl. C), 29C-32C (2000).
96. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infiximab: a large center experience. Am. J. Gastroenterol. 98(6), 1315-1324 (2003). (Pubitemid 36741529)
97. Fiorino G, Rovida S, Correale C et al. Emerging biologics in the treatment of infammatory bowel disease: what is around the corner? Curr. Drug Targets 11(2), 249-260 (2010).
98. Mannon PJ, Fuss IL, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351(20), 409-416 (2004). (Pubitemid 39482500)
99. D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 371 (9613), 660-670 (2008). (Pubitemid 351284485)
100. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infiximab from trough serum levels. Gut 59(1), 7-8 (2010).
101. Rutgeerts P, D'Haens G, Targan S et al. Effcacy and safety of retreatment with anti-tumor necrosis factor antibody (infiximab) to maintain remission in Crohn's disease. Gastroenterology 117(4), 761-769 (1999). (Pubitemid 29468216)